Next Generation PrEP II (R01)

The summary for the Next Generation PrEP II (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Next Generation PrEP II (R01)
	CFDA Number:	93.855
	CFDA Description:	Allergy, Immunology and Transplantation Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AI-11-023
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 30, 2011
	Creation Date:	Mar 30, 2011
	Original Closing Date for Applications:	Sep 08, 2011
	Current Closing Date for Applications:	Sep 08, 2011
	Archive Date:	Oct 09, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	3,200,000
	Federal Grant Award Ceiling:	300,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed.
Grant Description: Develop the basic and preclinical framework needed for development of second and subsequent generations of PrEP agents Create a rational pipeline for the discovery of New Molecular Entities (NMEs) and the identification of existing antiretrovirals (including those that are approved for HIV treatment, and those that are not approved but may have clinical data) that can be used for the next generation of PrEP agents Develop preclinical algorithms with clear go/no go criteria for identifying and prioritizing PrEP candidates for advancement to clinical evaluation Generate PK/PD models to assess protective effects at mucosal sites of HIV transmission Conduct proof-of-concept safety and efficacy studies in animal models
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ai-11-023.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Innovation for HIV Vaccine Discovery (R01); • NIAID Clinical Trial Implementation Cooperative Agreement (U01); • Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33); • Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01); • Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Inj...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers; • Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01); • Asthma and Allergic Diseases Cooperative Research Centers (U19)